ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

Merck Acquisition Benefits Patients and Investors

Share On Facebook
share on Linkedin
Print

Pharmaceutical giant Merck (NYSE:MRK) announced today that it has agreed to acquire Idenix Pharmaceuticals (NASDAQ:IDIX) for $3.85 billion. Even compared to the now defunct attempt of Pfizer (NYSE:PFE) to acquire AstraZeneca (LSE:AZN), this could be one of the biggest acquisitions of all time in this sector, not necessarily in volume, but in impact. It appears to be a marriage made in heaven.

©

The Deal

Merck will pay $24.50 per share in cash for each share of Idenix. That’s quite a premium considering the Idenix share price closed at 7.23 on Friday, 06 June, the highest is has been in the last 30 days. The Merck share price closed Friday at 57.85.

The Response

The Merck share price opened at 57.49 this morning, making it to 57.92 by 10:52 am. It is currently trading at 57.73. In effect, no real change. On the other hand, Idenix’ share price opened this morning at 24.01 after early trading, more than triple Friday’s close and almost equal to the Merck offer. So my $10,000 investment on Friday is now worth about $35,000.

The Purpose

According to the report, “Idenix is a biopharmaceutical company that focuses on developing treatments for human viral diseases, including hepatitis C. The company currently has three hepatitis C drug candidates in clinical development, the companies said. It has no products on the market.”

Merck President, Dr. Roger Perlmutter explained, “Idenix’s investigational hepatitis C candidates complement our promising therapies in development” and will help to develop a highly effective, once-daily, all-oral treatment.”

The Market

There are approximately 3.2 million Americans with the deadly hepatitis C viral infection. It is estimated that more than 170 million people are infected worldwide. The demand for a cure is great. Heretofore, Gilead Sciences (NASDAQ:GILD) has been able to produce the only truly recognized effective cure in the form of Solvadi.

Since we all know the supply and demand argument, we should not be surprised that Gilead charges $1,000 per pill. That makes the range of treatment cost in the US as high as $168,000, while the average treatment cost in the UK is £35,000 over a 12-week course of treatment. That’s not pricing a product, that’s holding the product for ransom.

The Irony

Gilead has already made $2.3 billion in sales revenue in the first quarter from the sales of Sovaldi. Merck is so confident that it will be able to deliver a much lower cost drug with a much shorter cure time (about a month), that it was willing to $3.85 billion to obtain the medication and to market it through its well-developed network.

The Beauty

Idenix has been lacking a path to market. Merck has been lacking “nucleoside/nucleotide chemistry and prodrug technologies.” Idenix brings that to the party.”

The deal has already been approved by the boards of both companies.

Perlmutter said that, “Idenix’s investigational hepatitis C candidates complement our promising therapies in development and will help advance our work to develop a highly effective, once-daily, all oral, ribavirin-free, pan-genotypic regimen that has a duration of treatment as short as possible for millions of patients in need around the world.”

Ron Renaud, President and CEO of Idenix agreed, saying, “his agreement creates shareholder value by positioning Idenix’s strong portfolio of candidates for future success with a leading healthcare company with the experience and commitment to develop fixed-dosed combinations with the potential to impact the global burden of hepatitis C.”

CLICK HERE TO REGISTER FOR FREE ON ADVFN, the world's leading stocks and shares information website, provides the private investor with all the latest high-tech trading tools and includes live price data streaming, stock quotes and the option to access 'Level 2' data on all of the world's key exchanges (LSE, NYSE, NASDAQ, Euronext etc).

This area of the ADVFN.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ADVFN Plc. ADVFN Plc does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ADVFN.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ADVFN.COM and is not intended to be relied upon by users in making (or refraining from making) any investment decisions. Authors may or may not have positions in stocks that they are discussing but it should be considered very likely that their opinions are aligned with their trading and that they hold positions in companies, forex, commodities and other instruments they discuss.

Leave A Reply

 
Do you want to write for our Newspaper? Get in touch: newspaper@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 | support@advfn.com